BioStem Technologies (BSEM) CFO exercises 10,634 RSUs into shares
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) reported that its Chief Financial Officer, Brandon Poe, exercised 10,634 Restricted Stock Units into an equal number of shares of common stock on August 11, 2026 at a stated price of $0.00 per share, resulting in direct ownership of 56,368 common shares. He continues to hold stock options exercisable for 38,814 common shares at $6.48 per share expiring in 2035 and 117,401 shares at $5.50 per share expiring in 2036, plus additional unvested Restricted Stock Units covering 8,469 and 96,909 underlying common shares that vest over time according to stated schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 10,634 shares
Net Buy
6 txns
Insider
POE BRANDON
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F3, F5 | 10,634 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,634 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Restricted Stock Units F3, F4 | -- | -- | -- |
| holding | Restricted Stock Units F3, F6 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 126,969 shares (Direct);
Common Stock — 56,368 shares (Direct);
Stock Options (Right to Buy) — 156,215 shares (Direct)
Footnotes (6)
- F1. These options vest according to the following schedule: 33% vested on August 11, 2026, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F2. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F4. These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
- F5. These restricted stock units vest according to the following schedule: 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period. Due to an administrative error, the vesting of the restricted stock units was not timely reported on a Form 4 within two business days of the applicable transaction date.
- F6. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
RSUs exercised into common stock: 10,634 shares
Exercise price for RSU conversion: $0.00 per share
Common shares owned after transaction: 56,368 shares
+5 more
8 metrics
RSUs exercised into common stock
10,634 shares
Restricted Stock Units converted to common stock on August 11, 2026
Exercise price for RSU conversion
$0.00 per share
Price reported for the 10,634 RSUs converted to common stock
Common shares owned after transaction
56,368 shares
Direct ownership of BioStem Technologies common stock following the Form 4 transaction
Stock options exercise price
$6.48 per share
Options expiring August 19, 2035 covering 38,814 underlying common shares
Underlying shares at $6.48 strike
38,814 shares
Underlying common stock for options with a $6.48 exercise price
Stock options exercise price
$5.50 per share
Options expiring February 11, 2036 covering 117,401 underlying common shares
Underlying shares at $5.50 strike
117,401 shares
Underlying common stock for options with a $5.50 exercise price
Unvested RSU underlying shares
8,469 and 96,909 shares
Common shares underlying remaining Restricted Stock Units vesting over time
Key Terms
Restricted Stock Units, Stock Options (Right to Buy), vest, contingent right, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with specified exercise prices and expirations"
vest financial
"These options vest according to the following schedule: 33% vested on August 11, 2026"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
equal quarterly installments financial
"with the remaining options vesting in equal quarterly installments over the subsequent"
FAQ
What equity transaction did BSEM CFO Brandon Poe report on this Form 4?
Brandon Poe reported the exercise of 10,634 Restricted Stock Units into 10,634 shares of BioStem Technologies common stock on August 11, 2026, at a stated price of $0.00 per share, as part of his equity compensation.
What stock options held by the BSEM CFO are disclosed in this filing?
The filing shows two option positions: options with an exercise price of $6.48 per share expiring on August 19, 2035 covering 38,814 underlying shares, and options with an exercise price of $5.50 per share expiring on February 11, 2036 covering 117,401 underlying shares.
What Restricted Stock Units remain outstanding for the BSEM CFO?
Brandon Poe has remaining Restricted Stock Units tied to 8,469 and 96,909 underlying shares of BioStem Technologies common stock. Footnotes state that these RSUs vest in equal quarterly installments over multi-year periods from their respective grant dates.
Were the BioStem Technologies RSUs subject to vesting schedules?
Yes. Footnotes state that some RSUs vested 33% on August 11, 2026 with the remainder vesting in equal quarterly installments over two years, and others will vest 33% on February 11, 2027, with the balance vesting quarterly over the following two years.
Does this BSEM Form 4 mention any reporting delay for prior RSU vesting?
One footnote explains that certain RSUs vesting on August 11, 2026 were not timely reported on a Form 4 within two business days due to an administrative error, and that this filing includes that disclosure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
